Hereditary Hemochromatosis

Coming Soon – Spring 2018: A clinical trial for patients with Hereditary Hemochromatosis.

Inclusion Criteria:

  • Patients with clinical diagnosis of hereditary hemochromatosis
  • Patients who are prescribed therapeutic phlebotomy for treatment of hereditary hemochromatosis
  • Patients with elevated serum ferritin and TSAT levels
  • Patient must be willing and able to provide written informed consent

Exclusion Criteria:

  • Patients receiving iron chelation therapy
  • Patients initiating phlebotomy treatments less than 6 months prior to the first dose of study drug
  • Pregnant or lactating women
  • Patients taking an immunosuppressive agent
  • Patients participating in an unapproved investigational drug or investigational therapeutic device within 30 days of study drug
  • Patients who are unwilling or unable to comply with the study protocol requirements
  • Patients with type 1 or type 2 diabetes
  • Patients must not have a medical condition that will interfere with the conduct of the clinical study


*Inclusion and Exclusion Criteria also listed on Additional Inclusion / Exclusion criteria may apply.

Qualified Candidates May Receive:

  • Treatment by licensed physicians
  • Compensation for time and travel
  • Study medication provided at no cost
  • In some cases transportation


Please contact our Research Team for more information! Call 616-328-5344.